The United States of America, As Represented by the Secretary, Department of Health and Human Services

Codagenix, Inc.

Cyril Lenouen

Peter L Collins

Ursula J Buchholz

Steffen Mueller

Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

Growing community of inventors

Bethesda, MD, United States of America

Cyril Lenouen